Status:
ACTIVE_NOT_RECRUITING
Evolocumab in STEMI
Lead Sponsor:
Sejong General Hospital
Collaborating Sponsors:
Samsung Medical Center
National Health Insurance Service Ilsan Hospital
Conditions:
ST Elevation Myocardial Infarction
Eligibility:
All Genders
30-80 years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary pe...
Detailed Description
The gold standard for the treatment of ST-segment elevation myocardial infarction (STEMI) is to rapidly restore myocardial blood flow through primary percutaneous coronary intervention (primary PCI) a...
Eligibility Criteria
Inclusion
- Typical ischemic chest pain persists for more than 30 minutes
- An elevation of an ST segment greater than 1 mm in two consecutive leads or new-onset left bundle branch block
- Presenting more than 12 hours after the onset of symptoms
Exclusion
- Previous history of myocardial infarction
- Previous history of coronary bypass surgery
- Cardiogenic shock that lasts more than 10 minutes or cardiac arrest
- Occlusion of the left main coronary artery
- Pregnant or have a plan of pregnancy
- Serum creatinine level is \>2.5mg/dL or dialysis is required
Key Trial Info
Start Date :
December 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT06081803
Start Date
December 5 2020
End Date
December 31 2025
Last Update
June 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sejong General Hospital
Bucheon-si, South Korea, 14574